ClinicalTrials.gg
CompletedNCT05718687Updated Jan 8, 2025Results posted

A GBT021601 ADME Microtracer Study in Healthy Volunteers

A Phase 1 interventional study of GBT021601 in Sickle Cell Disease, sponsored by Pfizer. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-08.

Sponsored by Pfizer · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.

Enrollment
20th of 27
9 · median 52
Started
2022
with 6 others
Phase 1
10 of 32
none open now
Registered
30th of 32
by date

Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 20th largest by enrollment of the 27 interventional ones that give a count, is one of 7 that started in 2022, is one of 10 in phase 1, and was the 30th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Anemia, Sickle Cell by Pfizer, or all of them as a file.
02

Study summary

An Open-label Study of GBT021601 in 8 to 10 healthy male or female participants to evaluate the absorption, distribution, metabolism, and excretion (ADME) of GBT021601.

Read the detailed description

This is an open-label Study administering GBT021601 as a single oral dose of 200 mg in healthy participants.

03

Conditions studied

  • Sickle Cell Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI): 18.0 to 27.0 kg/m2, inclusive, at screening.
  • Body weight ≥ 50 kg at screening
  • Females must be nonlactating and nonpregnant (as confirmed by a negative serum pregnancy test at screening and admission for all females), or of nonchildbearing potential (ie, either surgically sterilized or physiologically incapable of becoming pregnant, or at least 1 year [defined as at least 12 months no menses, and confirmed by a follicle-stimulating hormone test, at screening]).
  • () as estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula: ≥90 mL/min, at screening.

Exclusion criteria

Exclusion Criteria:

  • History or presence of conditions which, in the opinion of the Investigator, are known to interfere with the ADME of drugs, such as previous surgery on the gastrointestinal tract (including removal of parts of the stomach, bowel, liver, gall bladder, or pancreas). Participants who have a history of appendectomy are eligible for enrollment.
  • History of chronic constipation, or recent complaints of an irregular defecation
  • Significant and/or acute illness at screening or within 5 days prior to study drug administration that may impact safety assessments, in the opinion of the Investigator.
  • Known personal or family history of congenital long syndrome or known family history of sudden death.
  • Participation in another ADME study with a radiation burden >0.1 mSv in the period of 1 year prior to screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (actual)

Study arms

  • Experimental
    Treatment

    open-label GBT021601

    Drug: GBT021601

Interventions

  • Single oral dose of 200 mg GBT021601, containing \~74 kBq (\~2 µCi) of \[14C\]-GBT021601

06

What researchers measure

Primary outcomes

  1. GBT021601 Concentration in Whole Blood and Plasma at Predose

    Time frame: Predose (within 60 minutes prior to GBT021601 dosing)

  2. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at Predose

    Data reported in microgram equivalent per milliliter (mcgEq/mL).

    Time frame: Predose (within 60 minutes prior to 14C-GBT021601 dosing)

  3. GBT021601 Concentration in Whole Blood and Plasma at 0.25 Hours

    Time frame: 0.25 hours post dosing on Day 1

  4. 14C-GBT021601 Total Radioactivity Concentrations in Whole Blood and Plasma at 0.25 Hours

    Time frame: 0.25 hours post dosing on Day 1

  5. GBT021601 Concentration in Whole Blood and Plasma at 0.50 Hours

    Time frame: 0.50 hours post dosing on Day 1

  6. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 0.50 Hours

    Time frame: 0.50 hours post dosing on Day 1

  7. GBT021601 Concentration in Whole Blood and Plasma at 1 Hours

    Time frame: 1 hours post dosing on Day 1

  8. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1 Hours

    Time frame: 1 hours post dosing on Day 1

  9. GBT021601 Concentration in Whole Blood and Plasma at 2 Hours

    Time frame: 2 hours post dosing on Day 1

  10. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2 Hours

    Time frame: 2 hours post dosing on Day 1

  11. GBT021601 Concentration in Whole Blood and Plasma at 3 Hours

    Time frame: 3 hours post dosing on Day 1

  12. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3 Hours

    Time frame: 3 hours post dosing on Day 1

  13. GBT021601 Concentration in Whole Blood and Plasma at 4 Hours

    Time frame: 4 hours post dosing on Day 1

  14. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4 Hours

    Time frame: 4 hours post dosing on Day 1

  15. GBT021601 Concentration in Whole Blood and Plasma at 6 Hours

    Time frame: 6 hours post dosing on Day 1

  16. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 6 Hours

    Time frame: 6 hours post dosing on Day 1

  17. GBT021601 Concentration in Whole Blood and Plasma at 8 Hours

    Time frame: 8 hours post dosing on Day 1

  18. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 8 Hours

    Time frame: 8 hours post dosing on Day 1

  19. GBT021601 Concentration in Whole Blood and Plasma at 12 Hours

    Time frame: 12 hours post dosing on Day 1

  20. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 12 Hours

    Time frame: 12 hours post dosing on Day 1

  21. GBT021601 Concentration in Whole Blood and Plasma at 24 Hours

    Time frame: 24 hours post dosing on Day 1

  22. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 24 Hours

    Time frame: 24 hours post dosing on Day 1

  23. GBT021601 Concentration in Whole Blood and Plasma at 48 Hours

    Time frame: 48 hours post dosing

  24. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 48 Hours

    Time frame: 48 hours post dosing

  25. GBT021601 Concentration in Whole Blood and Plasma at 72 Hours

    Time frame: 72 hours post dosing

  26. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 72 Hours

    Time frame: 72 hours post dosing

  27. GBT021601 Concentration in Whole Blood and Plasma at 96 Hours

    Time frame: 96 hours post dosing

  28. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 96 Hours

    Time frame: 96 hours post dosing

  29. GBT021601 Concentration in Whole Blood and Plasma at 144 Hours

    Time frame: 144 hours post dosing

  30. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 144 Hours

    Time frame: 144 hours post dosing

  31. GBT021601 Concentration in Whole Blood and Plasma at 168 Hours

    Time frame: 168 hours post dosing

  32. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 168 Hours

    Time frame: 168 hours post dosing

  33. GBT021601 Concentration in Whole Blood and Plasma at 312 Hours

    Time frame: 312 hours post dosing

  34. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 312 Hours

    Time frame: 312 hours post dosing

  35. GBT021601 Concentration in Whole Blood and Plasma at 480 Hours

    Time frame: 480 hours post dosing

  36. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 480 Hours

    Time frame: 480 hours post dosing

  37. GBT021601 Concentration in Whole Blood and Plasma at 648 Hours

    Time frame: 648 hours post dosing

  38. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 648 Hours

    Time frame: 648 hours post dosing

  39. GBT021601 Concentration in Whole Blood and Plasma at 816 Hours

    Time frame: 816 hours post dosing

  40. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 816 Hours

    Time frame: 816 hours post dosing

  41. GBT021601 Concentration in Whole Blood and Plasma at 984 Hours

    Time frame: 984 hours post dosing

  42. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 984 Hours

    Time frame: 984 hours post dosing

  43. GBT021601 Concentration in Whole Blood and Plasma at 1320 Hours

    Time frame: 1320 hours post dosing

  44. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1320 Hours

    Time frame: 1320 hours post dosing

  45. GBT021601 Concentration in Whole Blood and Plasma at 1656 Hours

    Time frame: 1656 hours post dosing

  46. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1656 Hours

    Time frame: 1656 hours post dosing

  47. GBT021601 Concentration in Whole Blood and Plasma at 1992 Hours

    Time frame: 1992 hours post dosing

  48. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1992 Hours

    Time frame: 1992 hours post dosing

  49. GBT021601 Concentration in Whole Blood and Plasma at 2328 Hours

    Time frame: 2328 hours post dosing

  50. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2328 Hours

    Time frame: 2328 hours post dosing

  51. GBT021601 Concentration in Whole Blood and Plasma at 2664 Hours

    Time frame: 2664 hours post dosing

  52. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2664 Hours

    Time frame: 2664 hours post dosing

  53. GBT021601 Concentration in Whole Blood and Plasma at 3240 Hours

    Time frame: 3240 hours post dosing

  54. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3240 Hours

    Time frame: 3240 hours post dosing

  55. GBT021601 Concentration in Whole Blood and Plasma at 3576 Hours

    Time frame: 3576 hours post dosing

  56. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3576 Hours

    Time frame: 3576 hours post dosing

  57. GBT021601 Concentration in Whole Blood and Plasma at 4248 Hours

    Time frame: 4248 hours post dosing

  58. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4248 Hours

    Time frame: 4248 hours post dosing

  59. GBT021601 Concentration in Whole Blood and Plasma at 4920 Hours

    Time frame: 4920 hours post dosing

  60. 14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4920 Hours

    Time frame: 4920 hours post dosing

  61. Cumulative Amount of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces

    Data are reported as aggregate of all scheduled time points.

    Time frame: Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose

  62. Cumulative Fraction of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces

    Data are reported as aggregate of all scheduled time points.

    Time frame: Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose

  63. Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of GBT021601 in Whole Blood and Plasma

    Area under the plasma concentration-time curve up to 24 hours post dose. Data reported in Hour\*microgram/millimeter (h\*mcg/mL).

    Time frame: Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours

  64. Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of 14C-GBT021601 in Whole Blood and Plasma

    Area under the plasma concentration-time curve up to 24 hours postdose. Data reported in hour\*microgram equivalent/milliliter (h\*mcgEq/mL).

    Time frame: Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours

  65. Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  66. Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of 14C-GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  67. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of GBT021601 in Whole Blood and Plasma

    Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  68. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C-GBT021601 in Whole Blood and Plasma

    Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration and Kel is apparent terminal elimination rate constant.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  69. Maximum Observed Concentration (Cmax) of GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  70. Maximum Observed Concentration (Cmax) of 14C-GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  71. Time to Attain Maximum Observed Concentration (Tmax) of GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  72. Time to Attain Maximum Observed Concentration (Tmax) of 14C-GBT021601 in Whole Blood and Plasma

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  73. Apparent Terminal Elimination Half-Life (t1/2) of GBT021601 in Whole Blood and Plasma

    Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  74. Apparent Terminal Elimination Half-Life (t1/2) of 14C-GBT021601 in Whole Blood and Plasma

    Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  75. Renal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine

    Renal clearance was calculated as CLR = Ae0-inf/AUC0-inf. Where Ae indicates Cumulative amount of drug excreted and AUC0-inf indicates Area under the plasma concentration-time curve from time 0 to infinity.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  76. Apparent Volume of Distribution at Terminal Phase (Vz/F) of GBT021601 in Whole Blood and Plasma

    Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  77. Apparent Volume of Distribution at Terminal Phase (Vz/F) of 14C-GBT021601 in Whole Blood and Plasma

    Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  78. Apparent Total Clearance (CL/F) of GBT021601 in Whole Blood and Plasma

    Apparent total clearance, calculated as dose/AUC0-inf.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  79. Apparent Total Clearance (CL/F) of 14C-GBT021601 in Whole Blood and Plasma

    Apparent total clearance, calculated as dose/AUC0-inf.

    Time frame: Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose

  80. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-6 Hours

    Time frame: 0-6 hours post dose

  81. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 6-12 Hours

    Time frame: 6-12 hours post dose

  82. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 12-24 Hours

    Time frame: 12-24 hours post dose

  83. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-24 Hours

    Time frame: 0-24 hours post dose

  84. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 24 Hours

    Time frame: 24 hours post dose

  85. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 48 Hours

    Time frame: 48 hours post dose

  86. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 72 Hours

    Time frame: 72 hours post dose

  87. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 96 Hours

    Time frame: 96 hours post dose

  88. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 120 Hours

    Time frame: 120 hours post dose

  89. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 144 Hours

    Time frame: 144 hours post dose

  90. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 168 Hours

    Time frame: 168 hours post dose

  91. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 192 Hours

    Time frame: 192 hours post dose

  92. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 216 Hours

    Time frame: 216 hours post dose

  93. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 240 Hours

    Time frame: 240 hours post dose

  94. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 264 Hours

    Time frame: 264 hours post dose

  95. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 288 Hours

    Time frame: 288 hours post dose

  96. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 312 Hours

    Time frame: 312 hours post dose

  97. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 336 Hours

    Time frame: 336 hours post dose

  98. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 360 Hours

    Time frame: 360 hours post dose

  99. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 384 Hours

    Time frame: 384 hours post dose

  100. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 408 Hours

    Time frame: 408 hours post dose

  101. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 432 Hours

    Time frame: 432 hours post dose

  102. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 456 Hours

    Time frame: 456 hours post dose

  103. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 480 Hours

    Time frame: 480 hours post dose

  104. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 504 Hours

    Time frame: 504 hours post dose

  105. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 528 Hours

    Time frame: 528 hours post dose

  106. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 552 Hours

    Time frame: 552 hours post dose

  107. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 576 Hours

    Time frame: 576 hours post dose

  108. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 600 Hours

    Time frame: 600 hours post dose

  109. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 624 Hours

    Time frame: 624 hours post dose

  110. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 648 Hours

    Time frame: 648 hours post dose

  111. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 816 Hours

    Time frame: 816 hours post dose

  112. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 984 Hours

    Time frame: 984 hours post dose

  113. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1320 Hours

    Time frame: 1320 hours post dose

  114. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1656 Hours

    Time frame: 1656 hours post dose

  115. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1992 Hours

    Time frame: 1992 hours post dose

  116. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2328 Hours

    Time frame: 2328 hours post dose

  117. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2664 Hours

    Time frame: 2664 hours post dose

  118. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3240 Hours

    Time frame: 3240 hours post dose

  119. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3576 Hours

    Time frame: 3576 hours post dose

  120. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4248 Hours

    Time frame: 4248 hours post dose

  121. Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4920 Hours

    Time frame: 4920 hours post dose

Secondary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An Adverse event (AE) was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. TEAEs were those which occurred (or worsened) after the dose of study drug during the on-treatment period, defined as the period after the dose of study drug and through the minimum of (Study Day 57, study discontinuation).

    Time frame: From Day 1 up to maximum of Day 57

  2. Number of Participants With Clinically Significant Laboratory Values

    Blood and urine samples was collected for clinical laboratory assessments. Clinical Laboratory Values included Clinical chemistry: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin (total, direct, and indirect), blood urea nitrogen, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total protein, and uric acid. Hematology: leukocytes, erythrocytes, hematocrit, Hb, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count (ie, thrombocytes), RBC count, and white blood cell count etc. Urinalysis: determination of pH and specific gravity, and presence of bilirubin, blood, glucose, ketones, nitrite, protein, leukocytes, and urobilinogen etc. Coagulation, Serology, Drug and alcohol screen and Pregnancy test. Clinical significance was judged by investigator.

    Time frame: Day 1 of dosing to Day 207

  3. Number of Participants With Clinically Significant Vital Signs Values

    Systolic and diastolic blood pressure and pulse was recorded after the participant had rested for at least 5 minutes in the supine position. Body temperature and respiratory rate was also measured. Clinical significance was judged by investigator.

    Time frame: Day 1 of dosing to Day 207

  4. Number of Participants With Clinically Significant ECG Values

    Standard 12-lead ECGs were performed after the participant had rested quietly for more than 5 minutes in a supine position utilizing an ECG machine that was equipped with computer-based interval measurements. The following measurement was recorded: the heart rate (of \<45 or \>100 beats per minute (BPM) , PR interval, QT interval, QT interval corrected using Fridericia's formula (QTcF) of \>450 msec for males and \>470 msec for females, and QRS duration. Any cardiac rhythm other than sinus rhythm that was interpreted by the Investigator was clinically significant.

    Time frame: Day 1

  5. Number of Participants With Clinically Significant Physical Examination Values

    Physical Examination test included body weight and height. physical examination was conducted at screening. Clinical significance was judged by investigator.

    Time frame: Screening (-28 Day to -2 Day, day with respect to dosing)

07

Results

Posted Jan 8, 2025
Limitations and caveats
Data for metabolite profiling was not reported for \[14C\]-GBT021601 in whole blood and plasma because it was planned to be collected as part of separate, pooled analysis.

Participant flow

A total of 9 participants were enrolled in this study.

Participant flow — Overall Study
MilestoneGBT021601+[14C]-GBT021601
Started9
Completed6
Not completed3
Withdrew: Withdrawal by subject3

Outcome measures

PrimaryGBT021601 Concentration in Whole Blood and Plasma at Predose
Time frame:
Predose (within 60 minutes prior to GBT021601 dosing)
Reported as:
Mean · Microgram/ milliliter (mcg/mL)
GBT021601 Concentration in Whole Blood and Plasma at Predose
Microgram/ milliliter (mcg/mL)GBT021601+[14C]-GBT021601
Whole bloodNA ± NA
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at Predose

Data reported in microgram equivalent per milliliter (mcgEq/mL).

Time frame:
Predose (within 60 minutes prior to 14C-GBT021601 dosing)
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at Predose
mcgEq/mLGBT021601+[14C]-GBT021601
Whole blood0 ± 0
Plasma0 ± 0
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 0.25 Hours
Time frame:
0.25 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 0.25 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole blood6.368 ± 5.4178
Plasma0.46267 ± 0.373675
Primary14C-GBT021601 Total Radioactivity Concentrations in Whole Blood and Plasma at 0.25 Hours
Time frame:
0.25 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentrations in Whole Blood and Plasma at 0.25 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood5.8206 ± 4.64396
Plasma0.84819 ± 0.595349
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 0.50 Hours
Time frame:
0.50 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 0.50 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood17.33 ± 4.122
Plasma1.2338 ± 0.37097
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 0.50 Hours
Time frame:
0.50 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 0.50 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood16.45 ± 4.348
Plasma2.345 ± 0.6467
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 1 Hours
Time frame:
1 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 1 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood29.37 ± 4.520
Plasma1.433 ± 0.1997
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1 Hours
Time frame:
1 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood27.24 ± 4.590
Plasma2.913 ± 0.4117
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 2 Hours
Time frame:
2 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 2 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood31.92 ± 6.544
Plasma0.9228 ± 0.21798
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2 Hours
Time frame:
2 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood29.52 ± 5.586
Plasma2.089 ± 0.4195
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 3 Hours
Time frame:
3 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 3 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood31.92 ± 6.544
Plasma0.5974 ± 0.13629
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3 Hours
Time frame:
3 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood29.78 ± 5.540
Plasma1.502 ± 0.2753
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 4 Hours
Time frame:
4 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 4 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood34.96 ± 6.738
Plasma0.4539 ± 0.14820
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4 Hours
Time frame:
4 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood31.23 ± 6.483
Plasma1.2243 ± 0.32688
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 6 Hours
Time frame:
6 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 6 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood34.84 ± 7.996
Plasma0.3013 ± 0.07405
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 6 Hours
Time frame:
6 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 6 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood31.51 ± 7.104
Plasma0.8534 ± 0.19276
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 8 Hours
Time frame:
8 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 8 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood36.00 ± 8.979
Plasma0.2267 ± 0.06210
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 8 Hours
Time frame:
8 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 8 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood31.53 ± 8.016
Plasma0.6592 ± 0.13795
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 12 Hours
Time frame:
12 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 12 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood36.49 ± 10.844
Plasma0.1986 ± 0.05917
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 12 Hours
Time frame:
12 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 12 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood32.95 ± 7.459
Plasma0.5064 ± 0.11455
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 24 Hours
Time frame:
24 hours post dosing on Day 1
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 24 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood37.53 ± 8.855
Plasma0.1479 ± 0.03685
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 24 Hours
Time frame:
24 hours post dosing on Day 1
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 24 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood33.62 ± 7.819
Plasma0.3256 ± 0.06395
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 48 Hours
Time frame:
48 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 48 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood37.39 ± 9.904
Plasma0.1402 ± 0.02718
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 48 Hours
Time frame:
48 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 48 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood33.29 ± 7.384
Plasma0.2207 ± 0.03853
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 72 Hours
Time frame:
72 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 72 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood35.41 ± 7.642
Plasma0.1377 ± 0.03011
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 72 Hours
Time frame:
72 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 72 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood31.38 ± 6.475
Plasma0.1861 ± 0.03361
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 96 Hours
Time frame:
96 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 96 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood34.67 ± 7.339
Plasma0.12923 ± 0.026617
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 96 Hours
Time frame:
96 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 96 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood30.62 ± 5.839
Plasma0.1670 ± 0.03204
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 144 Hours
Time frame:
144 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 144 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood32.48 ± 7.257
Plasma0.11038 ± 0.016657
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 144 Hours
Time frame:
144 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 144 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood28.81 ± 5.988
Plasma0.1434 ± 0.02345
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 168 Hours
Time frame:
168 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 168 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood32.91 ± 7.603
Plasma0.12189 ± 0.020679
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 168 Hours
Time frame:
168 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 168 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood27.33 ± 5.329
Plasma0.1471 ± 0.03267
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 312 Hours
Time frame:
312 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 312 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood26.59 ± 5.353
Plasma0.11109 ± 0.024207
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 312 Hours
Time frame:
312 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 312 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood23.44 ± 3.976
Plasma0.1274 ± 0.01847
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 480 Hours
Time frame:
480 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 480 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood22.38 ± 3.991
Plasma0.08271 ± 0.014586
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 480 Hours
Time frame:
480 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 480 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood19.30 ± 2.743
Plasma0.09706 ± 0.010952
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 648 Hours
Time frame:
648 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 648 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood18.71 ± 3.597
Plasma0.07343 ± 0.011345
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 648 Hours
Time frame:
648 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 648 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood16.32 ± 2.161
Plasma0.08224 ± 0.007987
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 816 Hours
Time frame:
816 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 816 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood15.20 ± 1.553
Plasma0.06894 ± 0.011486
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 816 Hours
Time frame:
816 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 816 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood12.93 ± 1.403
Plasma0.08084 ± 0.005649
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 984 Hours
Time frame:
984 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 984 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood12.60 ± 1.715
Plasma0.05919 ± 0.006786
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 984 Hours
Time frame:
984 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 984 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood11.087 ± 1.4815
Plasma0.06646 ± 0.005689
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 1320 Hours
Time frame:
1320 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 1320 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood8.772 ± 1.1434
Plasma0.03829 ± 0.003602
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1320 Hours
Time frame:
1320 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1320 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood7.599 ± 1.1109
Plasma0.04387 ± 0.004128
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 1656 Hours
Time frame:
1656 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 1656 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood6.253 ± 0.9576
Plasma0.02809 ± 0.005965
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1656 Hours
Time frame:
1656 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1656 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood5.528 ± 1.0078
Plasma0.02835 ± 0.004387
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 1992 Hours
Time frame:
1992 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 1992 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood4.283 ± 0.7310
Plasma0.01881 ± 0.003921
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1992 Hours
Time frame:
1992 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 1992 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood3.667 ± 0.5431
Plasma0.01909 ± 0.004378
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 2328 Hours
Time frame:
2328 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 2328 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood2.997 ± 0.6994
Plasma0.01407 ± 0.007193
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2328 Hours
Time frame:
2328 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2328 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood2.677 ± 0.5212
Plasma0.013250 ± 0.0042927
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 2664 Hours
Time frame:
2664 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 2664 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood2.290 ± 0.4786
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2664 Hours
Time frame:
2664 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 2664 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood2.064 ± 0.3699
Plasma0.008206 ± 0.0031073
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 3240 Hours
Time frame:
3240 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 3240 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood1.1523 ± 0.38725
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3240 Hours
Time frame:
3240 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3240 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood0.9463 ± 0.30792
PlasmaNA ± NA
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 3576 Hours
Time frame:
3576 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 3576 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole Blood0.6097 ± 0.52801
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3576 Hours
Time frame:
3576 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 3576 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood0.6733 ± 0.24908
PlasmaNA ± NA
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 4248 Hours
Time frame:
4248 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 4248 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole BloodNA ± NA
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4248 Hours
Time frame:
4248 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4248 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood0.2745 ± 0.14637
PlasmaNA ± NA
PrimaryGBT021601 Concentration in Whole Blood and Plasma at 4920 Hours
Time frame:
4920 hours post dosing
Reported as:
Mean · mcg/mL
GBT021601 Concentration in Whole Blood and Plasma at 4920 Hours
mcg/mLGBT021601+[14C]-GBT021601
Whole BloodNA ± NA
PlasmaNA ± NA
Primary14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4920 Hours
Time frame:
4920 hours post dosing
Reported as:
Mean · mcgEq/mL
14C-GBT021601 Total Radioactivity Concentration in Whole Blood and Plasma at 4920 Hours
mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood0.2330 ± NA
PlasmaNA ± NA
PrimaryCumulative Amount of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces

Data are reported as aggregate of all scheduled time points.

Time frame:
Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose
Reported as:
Mean · milligram equivalents (mgEq)
Cumulative Amount of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces
milligram equivalents (mgEq)GBT021601+[14C]-GBT021601
Urine95.23 ± 10.153
Feces81.38 ± 12.668
PrimaryCumulative Fraction of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces

Data are reported as aggregate of all scheduled time points.

Time frame:
Day 1 (prior to dosing), after dosing from 0-6 hours, 6-12 hrs, 12-24 hrs postdose for urine, 24-hr intervals up to Day 29; 816 hrs , 984 hrs, 1320 hrs, 1656 hrs, 1992 hrs, 2328 hrs, 2664 hrs, 3240 hrs, 3576 hrs, 4248 hrs, and 4920 hrs post-dose
Reported as:
Mean · Percentage of administered drug
Cumulative Fraction of [14C]-GBT021601 Total Radioactivity Excreted in Urine and Feces
Percentage of administered drugGBT021601+[14C]-GBT021601
Urine47.24 ± 5.036
Feces40.37 ± 6.284
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of GBT021601 in Whole Blood and Plasma

Area under the plasma concentration-time curve up to 24 hours post dose. Data reported in Hour\*microgram/millimeter (h\*mcg/mL).

Time frame:
Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours
Reported as:
Geometric mean · h*mcg/mL
Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of GBT021601 in Whole Blood and Plasma
h*mcg/mLGBT021601+[14C]-GBT021601
Whole Blood824.1 ± 22.3
Plasma7.393 ± 20.0
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of 14C-GBT021601 in Whole Blood and Plasma

Area under the plasma concentration-time curve up to 24 hours postdose. Data reported in hour\*microgram equivalent/milliliter (h\*mcgEq/mL).

Time frame:
Day 1 (prior to dosing) at 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24 hours
Reported as:
Geometric mean · h*mcgEq/mL
Area Under the Plasma Concentration-Time Curve From Time Zero (0) to 24 Hours (AUC0-24) of 14C-GBT021601 in Whole Blood and Plasma
h*mcgEq/mLGBT021601+[14C]-GBT021601
Whole Blood741.8 ± 21.3
Plasma17.92 ± 19.2
PrimaryArea Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · h*mcg/mL
Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of GBT021601 in Whole Blood and Plasma
h*mcg/mLGBT021601+[14C]-GBT021601
Whole blood31481.7 ± 20.9
Plasma130.35 ± 16.7
PrimaryArea Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of 14C-GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · h*mcgEq/mL
Area Under the Concentration-Time From Time Zero to the Last Measurable Concentration (AUC0-last) of 14C-GBT021601 in Whole Blood and Plasma
h*mcgEq/mLGBT021601+[14C]-GBT021601
Whole blood27609.6 ± 18.5
Plasma165.7 ± 13.1
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of GBT021601 in Whole Blood and Plasma

Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · h*mcg/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of GBT021601 in Whole Blood and Plasma
h*mcg/mLGBT021601+[14C]-GBT021601
Whole blood35290.5 ± 12.1
Plasma150.7 ± 10.8
PrimaryArea Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C-GBT021601 in Whole Blood and Plasma

Area under the plasma concentration-time curve from time 0 to infinity calculated as: AUC0-inf=AUC0-t+Clast/kel, where Clast is the last measurable plasma concentration and Kel is apparent terminal elimination rate constant.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · h*mcgEq/mL
Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of 14C-GBT021601 in Whole Blood and Plasma
h*mcgEq/mLGBT021601+[14C]-GBT021601
Whole blood30636.1 ± 10.5
Plasma179.1 ± 8.8
PrimaryMaximum Observed Concentration (Cmax) of GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · mcg/mL
Maximum Observed Concentration (Cmax) of GBT021601 in Whole Blood and Plasma
mcg/mLGBT021601+[14C]-GBT021601
Whole blood40.06 ± 27.1
Plasma1.468 ± 14.0
PrimaryMaximum Observed Concentration (Cmax) of 14C-GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · mcgEq/mL
Maximum Observed Concentration (Cmax) of 14C-GBT021601 in Whole Blood and Plasma
mcgEq/mLGBT021601+[14C]-GBT021601
Whole blood34.05 ± 20.8
Plasma2.950 ± 12.5
PrimaryTime to Attain Maximum Observed Concentration (Tmax) of GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Median · Hour (h)
Time to Attain Maximum Observed Concentration (Tmax) of GBT021601 in Whole Blood and Plasma
Hour (h)GBT021601+[14C]-GBT021601
Whole blood24.000 (8.00 to 72.03)
Plasma1.000 (0.50 to 1.00)
PrimaryTime to Attain Maximum Observed Concentration (Tmax) of 14C-GBT021601 in Whole Blood and Plasma
Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Median · Hour
Time to Attain Maximum Observed Concentration (Tmax) of 14C-GBT021601 in Whole Blood and Plasma
HourGBT021601+[14C]-GBT021601
Whole blood24.000 (4.00 to 48.00)
Plasma1.000 (0.50 to 1.00)
PrimaryApparent Terminal Elimination Half-Life (t1/2) of GBT021601 in Whole Blood and Plasma

Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Mean · Hour
Apparent Terminal Elimination Half-Life (t1/2) of GBT021601 in Whole Blood and Plasma
HourGBT021601+[14C]-GBT021601
Whole blood647.8 ± 84.51
Plasma707.1 ± 112.32
PrimaryApparent Terminal Elimination Half-Life (t1/2) of 14C-GBT021601 in Whole Blood and Plasma

Apparent terminal elimination half-life, calculated as 0.693/kel where kel is Apparent terminal elimination rate constant.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Mean · Hour
Apparent Terminal Elimination Half-Life (t1/2) of 14C-GBT021601 in Whole Blood and Plasma
HourGBT021601+[14C]-GBT021601
Whole blood654.7 ± 92.46
Plasma588.9 ± 109.92
PrimaryRenal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine

Renal clearance was calculated as CLR = Ae0-inf/AUC0-inf. Where Ae indicates Cumulative amount of drug excreted and AUC0-inf indicates Area under the plasma concentration-time curve from time 0 to infinity.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · Liter/hour (L/h)
Renal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine
Liter/hour (L/h)GBT021601+[14C]-GBT021601
Renal Clearance (CLR) of GBT021601 and 14C-GBT021601 in Urine0.2755 ± 12.6
PrimaryApparent Volume of Distribution at Terminal Phase (Vz/F) of GBT021601 in Whole Blood and Plasma

Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · Liter (L)
Apparent Volume of Distribution at Terminal Phase (Vz/F) of GBT021601 in Whole Blood and Plasma
Liter (L)GBT021601+[14C]-GBT021601
Whole blood5.175 ± 18.3
Plasma1300.6 ± 15.5
PrimaryApparent Volume of Distribution at Terminal Phase (Vz/F) of 14C-GBT021601 in Whole Blood and Plasma

Apparent volume of distribution at terminal phase, calculated as: (CL/F) Apparent total clearance, calculated as dose/AUC0-inf/Kel.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · Liter
Apparent Volume of Distribution at Terminal Phase (Vz/F) of 14C-GBT021601 in Whole Blood and Plasma
LiterGBT021601+[14C]-GBT021601
Whole blood5.972 ± 15.9
Plasma906.1 ± 14.4
PrimaryApparent Total Clearance (CL/F) of GBT021601 in Whole Blood and Plasma

Apparent total clearance, calculated as dose/AUC0-inf.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · L/h
Apparent Total Clearance (CL/F) of GBT021601 in Whole Blood and Plasma
L/hGBT021601+[14C]-GBT021601
Whole blood0.005713 ± 12.1
Plasma1.338 ± 10.8
PrimaryApparent Total Clearance (CL/F) of 14C-GBT021601 in Whole Blood and Plasma

Apparent total clearance, calculated as dose/AUC0-inf.

Time frame:
Day 1 (prior to dosing), 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96, 144,168, 312, 480, 648, 816, 984,1320,1656,1992, 2328, 2664, 3240, 3576, 4248 and 4920 hours post-dose
Reported as:
Geometric mean · L/h
Apparent Total Clearance (CL/F) of 14C-GBT021601 in Whole Blood and Plasma
L/hGBT021601+[14C]-GBT021601
Whole blood0.006580 ± 10.5
Plasma1.1258 ± 8.8
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-6 Hours
Time frame:
0-6 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-6 Hours
mgEqGBT021601+[14C]-GBT021601
Urine13.123 ± 4.5812
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 6-12 Hours
Time frame:
6-12 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 6-12 Hours
mgEqGBT021601+[14C]-GBT021601
Urine16.611 ± 4.2333
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 12-24 Hours
Time frame:
12-24 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 12-24 Hours
mgEqGBT021601+[14C]-GBT021601
Urine19.70 ± 4.021
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-24 Hours
Time frame:
0-24 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 0-24 Hours
mgEqGBT021601+[14C]-GBT021601
Feces0.060486 ± 0.1389173
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 24 Hours
Time frame:
24 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 24 Hours
mgEqGBT021601+[14C]-GBT021601
Urine23.19 ± 4.305
Feces24.25 ± 9.726
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 48 Hours
Time frame:
48 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 48 Hours
mgEqGBT021601+[14C]-GBT021601
Urine25.50 ± 4.727
Feces33.17 ± 7.021
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 72 Hours
Time frame:
72 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 72 Hours
mgEqGBT021601+[14C]-GBT021601
Urine27.55 ± 5.112
Feces35.06 ± 8.909
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 96 Hours
Time frame:
96 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 96 Hours
mgEqGBT021601+[14C]-GBT021601
Urine29.35 ± 5.504
Feces37.31 ± 8.103
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 120 Hours
Time frame:
120 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 120 Hours
mgEqGBT021601+[14C]-GBT021601
Urine30.97 ± 5.791
Feces40.54 ± 4.600
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 144 Hours
Time frame:
144 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 144 Hours
mgEqGBT021601+[14C]-GBT021601
Urine32.88 ± 6.151
Feces39.51 ± 8.832
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 168 Hours
Time frame:
168 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 168 Hours
mgEqGBT021601+[14C]-GBT021601
Urine34.82 ± 6.438
Feces40.87 ± 7.673
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 192 Hours
Time frame:
192 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 192 Hours
mgEqGBT021601+[14C]-GBT021601
Urine36.72 ± 6.695
Feces44.39 ± 5.139
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 216 Hours
Time frame:
216 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 216 Hours
mgEqGBT021601+[14C]-GBT021601
Urine38.48 ± 6.926
Feces43.09 ± 9.219
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 240 Hours
Time frame:
240 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 240 Hours
mgEqGBT021601+[14C]-GBT021601
Urine40.22 ± 7.197
Feces43.54 ± 8.212
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 264 Hours
Time frame:
264 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 264 Hours
mgEqGBT021601+[14C]-GBT021601
Urine41.99 ± 7.402
Feces45.31 ± 8.482
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 288 Hours
Time frame:
288 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 288 Hours
mgEqGBT021601+[14C]-GBT021601
Urine43.65 ± 7.589
Feces44.72 ± 7.324
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 312 Hours
Time frame:
312 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 312 Hours
mgEqGBT021601+[14C]-GBT021601
Urine45.06 ± 7.759
Feces46.29 ± 9.018
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 336 Hours
Time frame:
336 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 336 Hours
mgEqGBT021601+[14C]-GBT021601
Urine46.50 ± 7.899
Feces50.24 ± 5.880
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 360 Hours
Time frame:
360 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 360 Hours
mgEqGBT021601+[14C]-GBT021601
Urine47.92 ± 8.085
Feces48.56 ± 8.315
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 384 Hours
Time frame:
384 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 384 Hours
mgEqGBT021601+[14C]-GBT021601
Urine49.41 ± 8.242
Feces52.20 ± 6.116
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 408 Hours
Time frame:
408 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 408 Hours
mgEqGBT021601+[14C]-GBT021601
Urine50.87 ± 8.418
Feces49.97 ± 9.261
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 432 Hours
Time frame:
432 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 432 Hours
mgEqGBT021601+[14C]-GBT021601
Urine52.24 ± 8.469
Feces50.84 ± 9.215
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 456 Hours
Time frame:
456 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 456 Hours
mgEqGBT021601+[14C]-GBT021601
Urine53.59 ± 8.564
Feces53.99 ± 6.398
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 480 Hours
Time frame:
480 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 480 Hours
mgEqGBT021601+[14C]-GBT021601
Urine54.81 ± 8.616
Feces52.89 ± 9.678
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 504 Hours
Time frame:
504 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 504 Hours
mgEqGBT021601+[14C]-GBT021601
Urine56.00 ± 8.649
Feces53.22 ± 9.709
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 528 Hours
Time frame:
528 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 528 Hours
mgEqGBT021601+[14C]-GBT021601
Urine57.15 ± 8.734
Feces56.23 ± 6.834
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 552 Hours
Time frame:
552 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 552 Hours
mgEqGBT021601+[14C]-GBT021601
Urine58.19 ± 8.845
Feces55.14 ± 9.750
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 576 Hours
Time frame:
576 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 576 Hours
mgEqGBT021601+[14C]-GBT021601
Urine59.25 ± 9.013
Feces55.39 ± 9.766
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 600 Hours
Time frame:
600 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 600 Hours
mgEqGBT021601+[14C]-GBT021601
Urine60.20 ± 9.159
Feces58.26 ± 7.116
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 624 Hours
Time frame:
624 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 624 Hours
mgEqGBT021601+[14C]-GBT021601
Urine61.13 ± 9.230
Feces57.17 ± 9.867
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 648 Hours
Time frame:
648 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 648 Hours
mgEqGBT021601+[14C]-GBT021601
Urine62.18 ± 9.313
Feces59.51 ± 8.648
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 816 Hours
Time frame:
816 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 816 Hours
mgEqGBT021601+[14C]-GBT021601
Urine67.24 ± 8.848
Feces62.99 ± 11.632
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 984 Hours
Time frame:
984 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 984 Hours
mgEqGBT021601+[14C]-GBT021601
Urine74.37 ± 9.568
Feces67.30 ± 11.537
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1320 Hours
Time frame:
1320 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1320 Hours
mgEqGBT021601+[14C]-GBT021601
Urine83.07 ± 9.068
Feces72.95 ± 12.135
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1656 Hours
Time frame:
1656 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1656 Hours
mgEqGBT021601+[14C]-GBT021601
Urine89.48 ± 9.168
Feces76.42 ± 13.642
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1992 Hours
Time frame:
1992 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 1992 Hours
mgEqGBT021601+[14C]-GBT021601
Urine93.46 ± 9.065
Feces79.01 ± 14.557
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2328 Hours
Time frame:
2328 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2328 Hours
mgEqGBT021601+[14C]-GBT021601
Urine92.85 ± 7.592
Feces84.14 ± 15.744
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2664 Hours
Time frame:
2664 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 2664 Hours
mgEqGBT021601+[14C]-GBT021601
Urine100.08 ± 12.033
Feces59.86 ± 0.613
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3240 Hours
Time frame:
3240 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3240 Hours
mgEqGBT021601+[14C]-GBT021601
Urine98.36 ± 10.969
Feces69.27 ± 13.344
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3576 Hours
Time frame:
3576 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 3576 Hours
mgEqGBT021601+[14C]-GBT021601
Urine98.96 ± 11.161
Feces69.62 ± 13.175
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4248 Hours
Time frame:
4248 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4248 Hours
mgEqGBT021601+[14C]-GBT021601
Urine93.30 ± 3.569
Feces85.10 ± NA
PrimaryDistribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4920 Hours
Time frame:
4920 hours post dose
Reported as:
Mean · mgEq
Distribution of 14C- GBT021601 Total Radioactivity in Urine and Feces at 4920 Hours
mgEqGBT021601+[14C]-GBT021601
Urine96.31 ± NA
Feces63.87 ± NA
SecondaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An Adverse event (AE) was any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure. TEAEs were those which occurred (or worsened) after the dose of study drug during the on-treatment period, defined as the period after the dose of study drug and through the minimum of (Study Day 57, study discontinuation).

Time frame:
From Day 1 up to maximum of Day 57
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsGBT021601+[14C]-GBT021601
Number of Participants With Treatment Emergent Adverse Events (TEAEs)4
SecondaryNumber of Participants With Clinically Significant Laboratory Values

Blood and urine samples was collected for clinical laboratory assessments. Clinical Laboratory Values included Clinical chemistry: alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin (total, direct, and indirect), blood urea nitrogen, calcium, chloride, creatinine, gamma glutamyl transferase, glucose, lactate dehydrogenase, magnesium, phosphorus, potassium, sodium, total protein, and uric acid. Hematology: leukocytes, erythrocytes, hematocrit, Hb, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count (ie, thrombocytes), RBC count, and white blood cell count etc. Urinalysis: determination of pH and specific gravity, and presence of bilirubin, blood, glucose, ketones, nitrite, protein, leukocytes, and urobilinogen etc. Coagulation, Serology, Drug and alcohol screen and Pregnancy test. Clinical significance was judged by investigator.

Time frame:
Day 1 of dosing to Day 207
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Laboratory Values
ParticipantsGBT021601+[14C]-GBT021601
Number of Participants With Clinically Significant Laboratory Values0
SecondaryNumber of Participants With Clinically Significant Vital Signs Values

Systolic and diastolic blood pressure and pulse was recorded after the participant had rested for at least 5 minutes in the supine position. Body temperature and respiratory rate was also measured. Clinical significance was judged by investigator.

Time frame:
Day 1 of dosing to Day 207
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Vital Signs Values
ParticipantsGBT021601+[14C]-GBT021601
Number of Participants With Clinically Significant Vital Signs Values0
SecondaryNumber of Participants With Clinically Significant ECG Values

Standard 12-lead ECGs were performed after the participant had rested quietly for more than 5 minutes in a supine position utilizing an ECG machine that was equipped with computer-based interval measurements. The following measurement was recorded: the heart rate (of \<45 or \>100 beats per minute (BPM) , PR interval, QT interval, QT interval corrected using Fridericia's formula (QTcF) of \>450 msec for males and \>470 msec for females, and QRS duration. Any cardiac rhythm other than sinus rhythm that was interpreted by the Investigator was clinically significant.

Time frame:
Day 1
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant ECG Values
ParticipantsGBT021601+[14C]-GBT021601
Number of Participants With Clinically Significant ECG Values0
SecondaryNumber of Participants With Clinically Significant Physical Examination Values

Physical Examination test included body weight and height. physical examination was conducted at screening. Clinical significance was judged by investigator.

Time frame:
Screening (-28 Day to -2 Day, day with respect to dosing)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Physical Examination Values
ParticipantsGBT021601+[14C]-GBT021601
Number of Participants With Clinically Significant Physical Examination Values0

Adverse events

Collected over From Day 1 up to maximum of Day 207. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GBT021601+[14C]-GBT0216010/9 (0%)0/9 (0%)4/9 (44.4%)
Most frequent other events
Most frequent other events
EventGBT021601+[14C]-GBT021601
HeadacheNervous system disorders2/9
NauseaGastrointestinal disorders1/9
COVID-19Infections and infestations1/9
Animal scratchInjury, poisoning and procedural complications1/9
PolymenorrhoeaReproductive system and breast disorders1/9
Dermatitis contactSkin and subcutaneous tissue disorders1/9

Baseline characteristics

Safety analysis set included all participants who had received 1 dose of GBT021601.

Age, Continuous
Age, Continuous(Years)GBT021601+[14C]-GBT021601
Mean33.6 ± 7.42
Sex: Female, Male
Sex: Female, Male(Participants)GBT021601+[14C]-GBT021601
Female2
Male7
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)GBT021601+[14C]-GBT021601
Hispanic or Latino0
Not Hispanic or Latino9
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)GBT021601+[14C]-GBT021601
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • ICON Early Phase Clinic, LLC
    Groningen, 9728, Netherlands
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Aug 2023, 7 months.

Results were first posted in Jan 2025, 1 year 4 months after primary completion.

Of 28 industry-sponsored phase 1 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's 7 months is below that.

Counting every sponsor, half of 58 studies reached it within 36 months; a quarter within 18 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Feb 8, 2023
StartActual
Dec 22, 2022
Primary completionActual
Aug 10, 2023
CompletionActual
Aug 10, 2023
Results first posted
Jan 8, 2025
Last update
Jan 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05718687
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Feb 8, 2023
Start date
Dec 22, 2022
Primary completion
Aug 10, 2023
Completion
Aug 10, 2023
Results posted
Jan 8, 2025
Last update
Jan 8, 2025

Study contacts

Pfizer Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Osivelotor

Start the discussion